13 healthcare companies reach $1B valuations this year

Thirteen healthcare companies have reached $1 billion in valuation this year––an especially notable achievement as the U.S. economy approaches a recession and investors pull back.

Business Insider reported on the 13 companies, underlying the decline in digital health investments this year. Digital-health startups raked in $6 billion in the first quarter of 2022, compared to $7.3 billion raised in the fourth quarter of 2021, Insider reported. Despite the decline, funding is still elevated above pre-pandemic levels, underscoring the huge interest in digital health among investors. 

News of the sky-high valuations also comes as healthcare is still evolving to meet the demands of the COVID-19 pandemic. As workforces and hospital and health system resources are stretched, telehealth has seen increased demand since the start of the pandemic––and many healthcare organizations have launched new virtual health programs.

 

Here are the 13 healthcare companies that made Insider’s list:

  • NexHealth - $1 billion valuation
  • Wheel - $1.02 billion valuation
  • Omada Health - $1.03 billion valuation
  • IntelyCare - $1.1 billion valuation
  • Viz.ai - $1.2 billion valuation
  • Biofourmis - $1.3 billion valuation
  • Clipboard Health - $1.3 billion valuation 
  • Clarify Health - $1.5 billion valuation
  • Athelas - $1.56 billion valuation
  • Transcarent - $1.62 billion valuation
  • BostonGene - $2.15 billion valuation
  • Oura Health - $2.55 billion valuation
  • Somatus - $2.56 billion valuation

Click the link below for the full story:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel. 

Kit Crancer, RBMA board member, speaks with Radiology Business about key legislative developments on the Hill that will affect the specialty.